Med24
Clinical Medicine 13. 10. 2026 • 2 min read • medical-news

Cardiac Microcurrent Therapy Raises Eyebrows in Heart Failure

PHOENIX -- Cardiac microcurrent (C-MIC) therapy may have great promise in heart failure (HF) -- almost "too good to be true," according to early studies. With accruing evidence, C-MIC therapy met more objective criteria...

Cardiac Microcurrent Therapy Raises Eyebrows in Heart Failure

Cardiac microcurrent (C-MIC) therapy is being investigated for heart failure (HF). Early studies, including the C-MIC II trial, showed potential benefits with a subcutaneous implant compared to controls. Analysis of CPET data revealed improvements in absolute peak VO2, peak metabolic equivalents, and percent-predicted peak VO2 in patients receiving C-MIC. A post hoc analysis of the C-MIC II trial, utilizing blinded core lab CPET results, confirmed these findings. The C-MIC II trial, involving 65 randomized patients, demonstrated improvements in left ventricular ejection fraction (LVEF), symptoms, functional capacity, and quality of life. A subsequent subcutaneous C-MIC approach, termed C-MIC III, showed comparable improvements in LVEF, 6-minute walking distance, and quality of life scores when compared to a surgical implant group. Initial results from C-MIC III involved 10 patients. Future research, C-MIC IV, will include a sham-controlled crossover trial with 60 patients and will investigate potential interference from existing implants, such as implantable cardioverter-defibrillators. Concerns remain regarding infection rates associated with the subcutaneous device, with one infection reported in the C-MIC III study.

Sponsored content

Original Scientific Source
medical-news
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Advertisement